MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+8.2%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$667M
AUM Growth
+$667M
(+3.6%)
Cap. Flow
+$8.21M
Cap. Flow
% of AUM
1.23%
Top 10 Holdings %
Top 10 Hldgs %
55.8%
Holding
54
New
10
Increased
20
Reduced
7
Closed
11
Top Buys
| 1 |
Avidity Biosciences
RNA
|
$25.9M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$19.7M |
| 3 |
Twist Bioscience
TWST
|
$13.3M |
| 4 |
Aquestive Therapeutics
AQST
|
$8.95M |
| 5 |
Janux Therapeutics
JANX
|
$7.77M |
Top Sells
| 1 |
Alkermes
ALKS
|
$13.4M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$12.6M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$11M |
| 4 |
Xeris Biopharma Holdings
XERS
|
$10.9M |
| 5 |
Axsome Therapeutics
AXSM
|
$10.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$445M
| $128M | 19.21% | 7,648,268 | – | – |
|
2
Insmed
INSM
$28.8B
| $44.9M | 6.74% | 615,391 | – | – |
|
3
Olema Pharmaceuticals
OLMA
$375M
| $32M | 4.8% | 2,680,596 +25,729 | +1% | +$307K |
|
|
4
Avidity Biosciences
RNA
$5.99B
| $31.6M | 4.75% | 688,975 +563,975 | +451% | +$25.9M |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $26.9M | 4.03% | 525,845 -31,339 | -6% | -$1.6M |
|
6
Edgewise Therapeutics
EWTX
$1.51B
| $24.5M | 3.67% | 917,166 +176,505 | +24% | +$4.71M |
|
7
Iovance Biotherapeutics
IOVA
$807M
| $22.6M | 3.39% | 2,406,714 +40,000 | +2% | +$376K |
|
8
Natera
NTRA
$23.1B
| $22.5M | 3.37% | 177,099 +2,288 | +1% | +$290K |
|
|
9
Rocket Pharmaceuticals
RCKT
$354M
| $19.7M | 2.95% | +1,066,373 | New | +$19.7M |
|
10
Mirum Pharmaceuticals
MIRM
$3.71B
| $19.2M | 2.88% | 492,723 +154 | +0% | +$6.01K |
|
11
Ultragenyx Pharmaceutical
RARE
$2.89B
| $18.3M | 2.75% | 329,733 -50,819 | -13% | -$2.82M |
|
12
iTeos Therapeutics
ITOS
| $17.8M | 2.67% | 1,745,943 | – | – |
|
13
MoonLake Immunotherapeutics
MLTX
$3.54B
| $17.6M | 2.64% | 349,063 +5,828 | +2% | +$294K |
|
14
Lantheus
LNTH
$3.73B
| $16.5M | 2.47% | 150,182 +182 | +0.1% | +$20K |
|
15
Madrigal Pharmaceuticals
MDGL
$9.76B
| $15.4M | 2.3% | 72,395 +1,210 | +2% | +$257K |
|
16
Disc Medicine
IRON
$2.07B
| $15.3M | 2.3% | 311,761 +6,103 | +2% | +$300K |
|
17
Relay Therapeutics
RLAY
$619M
| $14.4M | 2.16% | 2,033,041 +758,582 | +60% | +$5.37M |
|
|
18
Twist Bioscience
TWST
$1.63B
| $13.3M | 2% | +294,930 | New | +$13.3M |
|
19
Revolution Medicines
RVMD
$7.1B
| $13.2M | 1.98% | 291,391 +1,995 | +0.7% | +$90.5K |
|
20
Guardant Health
GH
$8.41B
| $11.5M | 1.72% | 499,170 -830 | -0.2% | -$19K |
|
21
Akero Therapeutics
AKRO
$3.74B
| $11.3M | 1.69% | 392,544 +6,554 | +2% | +$188K |
|
22
KalVista Pharmaceuticals
KALV
$678M
| $10.4M | 1.56% | 896,915 +14,978 | +2% | +$173K |
|
23
Compass Therapeutics
CMPX
$483M
| $10.4M | 1.56% | 5,641,894 +636,808 | +13% | +$1.17M |
|
24
Cartesian Therapeutics
RNAC
$261M
| $10.1M | 1.52% | 629,423 +369,727 | +142% | +$5.96M |
|
25
Sutro Biopharma
STRO
$72.7M
| $9.8M | 1.47% | 2,832,064 -211,282 | -7% | -$731K |
|